Knight Therapeutics sees 2023 revenue C$325M-C$335M

For fiscal 2023, Knight has updated its financial guidance on revenues and expects to generate between C$325 million to C$335 million in revenues an increase of C$15 million on the lower end and C$5 million on the upper end of the range. The adjusted EBITDA is expected to be approximately 18% of revenues. The increase in the financial outlook is primarily due to the Q4-23 MOH Order, as well as improvement in forecasted LATAM currencies against the Canadian dollar.